Veradermics, Inc - 8-K Filing

Veradermics reports positive topline 12-month data from Phase 2/3 Study '302' for VDPHL01 in male pattern hair loss. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 14:04 UTC

Tickers: $MANE

Read the full article at SEC EDGAR

Part of the story Veradermics, Inc - 8-K Filing (3 articles)

More Regulatory news

SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC